Litcius/Paper detail

Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study

Olga Nigro, Graziella Pinotti, Federica De Galitiis, Francesca Romana Di Pietro, Raffaele Giusti, Marco Filetti, Melissa Bersanelli, Alessandro Lazzarin, Paola Bordi, Annamaria Catino, Pamela Pizzutilo, Domenico Galetta, Paolo Marchetti, Andrea Botticelli, Simone Scagnoli, Marco Russano, Daniele Santini, Mariangela Torniai, Rossana Berardi, Biagio Ricciuti, Andrea De Giglio, Rita Chiari, Alessandro Russo, Vincenzo Adamo, Marianna Tudini, Rosa Rita Silva, Elena Bolzacchini, Monica Giordano, Pietro Di Marino, Michele De Tursi, Erika Rijavec, Michele Ghidini, I. Vallini, Luigia Stefania Stucci, Marco Tucci, Laura Pala, Fabio Conforti, Paola Queirolo, Enrica T. Tanda, Francesco Spagnolo, Federica Cecchi, Sergio Bracarda, Serena Macrini, Matteo Santoni, Nicola Battelli, Maria Concetta Fargnoli, Giampiero Porzio, Alessandro Tuzi, Matteo B. Suter, Corrado Ficorella, Alessio Cortellini

2020European Journal of Cancer69 citationsDOI

Topics & Concepts

MedicineHazard ratioAdverse effectConfidence intervalInternal medicineProportional hazards modelRetrospective cohort studySurgeryCancer Immunotherapy and BiomarkersCAR-T cell therapy researchColorectal Cancer Treatments and Studies
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study | Litcius